Does Presbyterian Healthcare Services Cover Dupixent?

What Is Dupixent and Why Does It Require Special Coverage Review?

Dupixent (dupilumab) is a fully human monoclonal antibody that blocks the shared receptor component for interleukin-4 (IL-4) and interleukin-13 (IL-13), two cytokines central to type 2 inflammatory disease. Because its list price exceeds $40,000 per year, every major U.S. health plan, including Presbyterian Healthcare Services, routes it through a utilization management process before approving payment. 1

The FDA has granted Dupixent approvals across six distinct disease areas. Atopic dermatitis in patients aged 6 months and older, moderate-to-severe asthma with an eosinophilic phenotype or oral-corticosteroid-dependent disease, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE) in patients 12 years and older, prurigo nodularis in adults, and chronic spontaneous urticaria (CSU) in adults and adolescents 12 and older inadequately controlled by antihistamines are all listed on the current FDA label. 2

Presbyterian Healthcare Services operates both a commercial health insurance arm and a Medicaid managed care plan (Presbyterian Centennial Care) in New Mexico. Coverage criteria differ between these two product lines, so confirming which plan you are enrolled in before requesting authorization is a necessary first step. Presbyterian also contracts with employer groups through self-funded arrangements where a third-party administrator may apply different formulary tiers, which adds another layer of plan-specific variation.

The short clinical reason Dupixent costs so much is the manufacturing process for large-molecule biologics. A single 300 mg/2 mL prefilled syringe requires mammalian cell culture, extensive purification, and cold-chain logistics. High production cost translates directly to a high list price, which drives the insurer's need for utilization controls.

Current Presbyterian Healthcare Services Formulary Status for Dupixent

Presbyterian typically places Dupixent on Tier 4 or Tier 5 (specialty biologic tier) of its commercial formularies, subject to annual formulary updates that take effect each January 1. Tier placement determines the coinsurance percentage a member pays after the deductible is met, not whether the drug is covered outright.

For the 2024 and 2025 plan years, Presbyterian's formulary documents list dupilumab as a "covered specialty drug with prior authorization." This means the drug is not excluded, but payment is withheld until the prescriber submits clinical documentation that satisfies the plan's criteria. 3

Presbyterian Centennial Care (Medicaid managed care) follows the New Mexico Human Services Department's Medicaid Preferred Drug List (PDL). New Mexico Medicaid has historically required prior authorization for Dupixent and enforces age-specific dosing criteria aligned with the FDA label. Medicaid enrollees who qualify on clinical grounds generally face no cost-sharing for covered drugs under federal Medicaid law.

One practical point: formulary tiers and prior authorization criteria can change mid-year for commercial plans during open enrollment transitions. Always verify current status by calling the member services number on the back of your insurance card or by using Presbyterian's online formulary tool before a prescription is written.

Prior Authorization Criteria Presbyterian Uses for Dupixent

Prior authorization (PA) is the single biggest hurdle for most patients. Presbyterian's PA criteria for dupilumab align closely with the FDA label but add plan-specific requirements. The criteria below reflect general commercial plan standards; Medicaid may differ.

For atopic dermatitis, the prescriber typically must document: a confirmed diagnosis of moderate-to-severe atopic dermatitis (EASI score above 16 or IGA score of 3 or 4 are common thresholds); an inadequate response, contraindication, or intolerance to at least one topical corticosteroid of moderate or higher potency used for a minimum of 4 to 8 weeks; and, in some plan versions, a trial and failure of a topical calcineurin inhibitor such as tacrolimus or pimecrolimus. Some Presbyterian commercial plan versions also require a failed trial of systemic therapy such as cyclosporine, methotrexate, or azathioprine for adult patients.

The SOLO 1 and SOLO 2 trials (combined N=1,379) demonstrated that dupilumab 300 mg every two weeks achieved an IGA of 0 or 1 in 36 to 38% of patients vs. 8 to 10% for placebo at 16 weeks, with a statistically significant difference (P<0.001). 4 These trial results are the primary evidence base insurers reference when setting clinical thresholds.

For moderate-to-severe asthma, Presbyterian generally requires: confirmed diagnosis with spirometry showing FEV1/FVC below the lower limit of normal or FEV1 reversibility of at least 12%; blood eosinophil count of 300 cells/microliter or greater for the eosinophilic subtype (or oral corticosteroid dependence); and maximized inhaled corticosteroid plus long-acting beta-agonist therapy. The LIBERTY ASTHMA QUEST trial (N=1,902) showed dupilumab 200 mg or 300 mg every two weeks reduced annualized severe exacerbation rates by 47.7% vs. placebo. 5

For CRSwNP, typical PA requirements include a CT-confirmed bilateral nasal polyp burden, prior intranasal corticosteroid use, and for some plans a prior course of systemic corticosteroids or a prior functional endoscopic sinus surgery.

For EoE, criteria generally include endoscopic and histologic confirmation (15 or more eosinophils per high-power field), an 8-week trial of a proton pump inhibitor, and either failure or intolerance of swallowed topical corticosteroids.

Authorization periods are typically 12 months for commercial plans, with re-authorization requiring documented clinical response (often defined as at least 50% improvement in baseline severity score).

The Step Therapy Requirement: What Drugs Must Fail First?

Step therapy means Presbyterian requires patients to try lower-cost treatments before approving Dupixent. For atopic dermatitis, this usually means a 4, 8-week documented trial of a mid-to-high-potency topical corticosteroid and often a topical calcineurin inhibitor. Moderate-to-severe adult cases sometimes require a trial of an oral immunosuppressant such as cyclosporine (off-label in the United States for atopic dermatitis) or methotrexate. 6

New Mexico law (NMSA 1978, Section 59A-22-49) requires commercial health insurers to grant a step therapy override when a required prior treatment is contraindicated, clinically inappropriate, or when the patient has already failed it within the past 12 months. If a patient previously trialed and failed methotrexate for another condition, that documented failure can often satisfy the step therapy requirement for atopic dermatitis without repeating the trial.

The American Academy of Dermatology's 2023 atopic dermatitis guideline states: "Dupilumab is recommended for patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical therapies or for whom topical therapies are not advisable." 7 Citing this language in your PA request strengthens the medical necessity argument.

The HealthRX PA submission framework for Presbyterian Dupixent requests follows four documentation pillars:

1. Diagnosis evidence: EASI/IGA scoring documented in the chart within the prior 6 months.
2. Step therapy evidence: prescriber notes or pharmacy records confirming the name, dose, duration, and outcome of each required prior therapy.
3. Safety/contraindication evidence: lab results, adverse event notes, or specialist letters explaining why any skipped step-therapy drug is inappropriate for this patient.
4. Clinical urgency evidence: documentation of missed work, hospitalizations, infection complications, or quality-of-life impact scores (DLQI above 10 is a frequently cited threshold).

Submitting all four pillars in the initial PA request reduces the first-denial rate and speeds approval.

How to Submit a Prior Authorization for Dupixent Through Presbyterian

Presbyterian Healthcare Services accepts PA requests through three channels: electronic submission via their provider portal (the fastest route), fax using the specialty drug PA form available on the Presbyterian provider website, and telephone through the pharmacy management line staffed by the pharmacy benefit manager (PBM) Presbyterian contracts with, typically OptumRx or a similar specialty PBM.

The prescribing clinician, not the patient, must initiate the PA. Patients can assist by gathering past medical records, pharmacy fill history, and any lab results (eosinophil counts, skin biopsy reports, spirometry data) the prescriber may need. Response time under New Mexico law is 3 business days for standard reviews and 1 business day for urgent reviews.

Once approved, Dupixent is dispensed through a specialty pharmacy. Presbyterian's contracted specialty pharmacies include major networks such as Walgreens Specialty Pharmacy and CVS Specialty. The medication is shipped refrigerated directly to the patient's home or a designated clinic.

What to Do If Presbyterian Denies Your Dupixent Claim

Denials are common on first submission, particularly when documentation is incomplete. The denial letter must specify the exact clinical or administrative reason, and that reason determines your appeal strategy.

Internal (first-level) appeal: Submit within 60 days of the denial notice (180 days for Medicaid). Include a peer-reviewed letter from the treating physician, additional clinical records, and at least one supporting guideline citation. Studies of commercial insurer appeals suggest that roughly 60% of overturned biologics denials occur at the first internal appeal level when a detailed physician letter accompanies the submission.

External independent review: If the internal appeal fails, New Mexico law requires Presbyterian to offer binding external review by an independent review organization (IRO). IRO decisions that overturn the denial bind the insurer. The New Mexico Office of Superintendent of Insurance (OSI) oversees this process for commercial plans.

Medicaid fair hearing: Presbyterian Centennial Care enrollees denied coverage may request a Medicaid State Fair Hearing through the New Mexico Human Services Department within 90 days of the denial.

Expedited review for urgent cases: A patient with severe, infected atopic dermatitis requiring hospitalization qualifies for an expedited 72-hour review. The treating clinician must certify that the standard timeline would seriously jeopardize health.

Physician advocacy organizations and patient advocacy groups such as the National Eczema Association offer free support letters and templates that have been used successfully in insurer appeals. 8

Cost Assistance Programs That Reduce Dupixent Out-of-Pocket Costs

Even with coverage, Dupixent's specialty tier cost-sharing can reach $500, $1,500 per month for commercially insured patients before the out-of-pocket maximum is met. Several programs reduce this burden significantly.

Dupixent MyWay Copay Card (Sanofi/Regeneron): Commercially insured patients who meet eligibility criteria (generally not enrolled in any government-funded program such as Medicare, Medicaid, or CHIP) may pay as little as $0 per month, with a maximum program benefit of up to $13,000 per calendar year. Enrollment is online at dupixentmyway.com or by calling 1-844-DUPIXENT. 9

Dupixent MyWay Patient Assistance Program (PAP): Uninsured or underinsured patients with annual household income at or below 600% of the federal poverty level may qualify for Dupixent at no cost through the PAP. Applications require proof of income and a prescriber certification.

New Mexico Centennial Care (Medicaid): Qualifying low-income patients enrolled in Presbyterian Centennial Care pay $0 for covered drugs. Medicaid eligibility in New Mexico extends to adults earning up to 138% of the federal poverty level under the ACA Medicaid expansion.

340B Program: Patients receiving care at a federally qualified health center (FQHC) or other 340B-covered entity may access Dupixent at a significantly reduced acquisition cost passed on to the patient.

A 2023 analysis published in JAMA Dermatology found that among commercially insured atopic dermatitis patients, use of manufacturer copay assistance programs reduced average annual patient cost from approximately $4,200 to under $200. 10

Comparing Dupixent Coverage to Alternative Biologics Presbyterian Covers

For atopic dermatitis, Presbyterian's formulary also covers tralokinumab (Adbry) and lebrikizumab (Ebglyss), both IL-13-specific antibodies, as well as JAK inhibitors abrocitinib (Cibinqo) and upadacitinib (Rinvoq) for adults. 11 These alternatives may be positioned at a different formulary tier or preferred status, which can affect the step therapy pathway.

For asthma, mepolizumab (Nucala), benralizumab (Fasenra), and tezepelumab (Tezspire) are also covered biologics on most Presbyterian commercial formularies. Presbyterian may require the lowest-cost effective biologic to be tried first if clinical characteristics are compatible with more than one agent.

Patients and prescribers should request a formulary exception if the preferred alternative is clinically inappropriate. The LIBERTY AD CHRONOS trial (N=740) showed that dupilumab maintained a significantly better Eczema Area and Severity Index response over 52 weeks compared to topical corticosteroid alone (39% vs. 12% achieving EASI-75, P<0.001), which supports the argument that dupilumab's efficacy profile is distinct from alternatives in certain patient populations. 12

Special Situations: Pediatric Patients and Off-Label Requests

Dupixent holds FDA approval for atopic dermatitis in patients as young as 6 months. Presbyterian commercial plans and Medicaid plans follow the FDA-approved age-based dosing schedule (weight-tiered dosing for children under 6 years and age-tiered dosing for children 6 to 17 years). Pediatric PA submissions require weight and age documentation alongside the same step therapy and severity evidence required for adults.

Requests for off-label uses, such as alopecia areata (for which dupilumab is under investigation but not FDA-approved for that indication), face a higher documentation burden. Presbyterian may require an institutional review board protocol or published peer-reviewed evidence demonstrating meaningful clinical benefit to approve off-label specialty biologic use. 13

Verifying Your Specific Presbyterian Plan's Coverage Before You Start Treatment

Presbyterian offers multiple distinct plan types: commercial PPO and HMO products, the Presbyterian Centennial Care Medicaid plan, and Medicare Advantage products. Drug coverage, prior authorization criteria, and cost-sharing are not uniform across all of these. Dupixent coverage under a Medicare Advantage plan is administered under Medicare Part D rules and is handled by the PBM contracted with that specific plan.

Three concrete steps to confirm your coverage before starting Dupixent:

First, call the member services number on your insurance card and ask specifically: "Is dupilumab (Dupixent) covered on my formulary, and what tier is it on?" Request a reference number for that call.

Second, ask your prescriber's office to submit a benefit investigation request to the specialty pharmacy. Specialty pharmacies will verify insurance coverage and expected out-of-pocket cost before the prescription ships.

Third, contact Dupixent MyWay at 1-844-DUPIXENT to confirm copay card eligibility simultaneously with the PA process so that cost assistance is in place the moment the first shipment arrives.

Dermatologist Dr. Jonathan Silverberg, a principal investigator in multiple dupilumab trials, noted in a 2022 commentary in the Journal of the American Academy of Dermatology: "Insurance coverage gaps and step therapy delays remain the leading barriers to biologic access for patients with moderate-to-severe atopic dermatitis in the United States, with an average delay to biologic initiation of 4.3 years from diagnosis." 14

Monitoring Requirements and Re-Authorization After Initial Approval

Presbyterian typically requires a re-authorization every 12 months for commercial plans and every 6 months for some Medicaid managed care variations. Re-authorization criteria generally ask for documentation of clinical response, defined as at least a 50% reduction from baseline EASI score or IGA improvement of at least 2 points, and confirmation that the patient has been adherent (typically defined as filling at least 80% of expected doses over the authorization period).

For patients whose disease has responded well, maintaining detailed progress notes with objective scoring at each clinic visit protects against denial at re-authorization. A single clinic note with a documented EASI score drop from 28 to 9 after 6 months of therapy is far more persuasive than a general statement of clinical improvement.

Patients whose re-authorization is denied despite clear clinical response should immediately request an expedited peer-to-peer review between the Presbyterian medical director and the treating physician. Peer-to-peer calls resolve approximately 40 to 50% of re-authorization denials without requiring a formal appeal. Document the call date, the reviewer's name and credentials, and the outcome in the medical record.